Ipratropium bromide in asthma. A review of the literature.
In comparative studies of asthma, ipratropium bromide has been shown to have a slower onset of bronchodilator action but a longer duration of effect than beta agonists. An additive effect of ipratropium and beta agonists has been demonstrated, in addition to prolongation of the bronchodilator response. Most studies do not show a definite difference in responsiveness of atopic versus nonatopic asthmatic patients; there are, however, reports indicating a greater responsiveness to anticholinergic agents than to beta agonists in patients with chronic bronchitis and emphysema. Ipratropium has been shown not to affect mucociliary clearance, sputum volume, or viscosity. It effectively inhibits the bronchial response to methacholine and, to a lesser degree, to histamine, serotonin, bradykinin, and antigen. Protection against exercise-induced asthma with this drug has been variable, but ipratropium has been found particularly useful in psychogenic asthma. Its role in occupational asthma remains to be determined.
D000375:Aging / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology; D001286:Atropine Derivatives / Q000627:therapeutic use*; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D009241:Ipratropium / Q000009:adverse effects / Q000627:therapeutic use*; D009784:Occupational Diseases / Q000188:drug therapy; D012727:Sex Characteristics; D012907:Smoking
D001286:Atropine Derivatives; D001993:Bronchodilator Agents; D009241:Ipratropium